title: Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
abstract: Angiotensin II type 1 receptor (AT1R) promotes tumor invasion, migration, metastasis and angiogenesis. We explored the potential antitumor effects of AT1R antagonists in breast cancer. We found that angiotensin II promoted cell proliferation and upregulated the expression of vascular endothelial growth factor A (VEGF-A) in MCF-7 cells. Losartan downregulated the expression of VEGF-A in MCF-7 cells treated with angiotensin II. Candesartan downregulated the expression of VEGF-A in mice bearing MCF-7 xenografts and inhibited tumor growth and angiogenesis. AT1R and VEGF-A expression correlated with increased microvascular density in 102 breast cancer patients. Our data suggest that AT1R antagonists might be useful to suppress breast cancer by inhibiting the angiotensin II.
authors.affiliation: Department of Internal Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin 150040, Heilongjiang Province, China.
authors.forename: Xuesong
authors.initials: X
authors.lastname: Chen
authors.forename: Qingwei
authors.initials: Q
authors.lastname: Meng
authors.forename: Yanbin
authors.initials: Y
authors.lastname: Zhao
authors.forename: Meiyan
authors.initials: M
authors.lastname: Liu
authors.forename: Dandan
authors.initials: D
authors.lastname: Li
authors.forename: Yanmei
authors.initials: Y
authors.lastname: Yang
authors.forename: Lichun
authors.initials: L
authors.lastname: Sun
authors.forename: Guangjie
authors.initials: G
authors.lastname: Sui
authors.forename: Li
authors.initials: L
authors.lastname: Cai
authors.forename: Xiaoqun
authors.initials: X
authors.lastname: Dong
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D019808:Losartan / Q000494:pharmacology; D061986:MCF-7 Cells; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism*; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics / Q000378:metabolism*; D047368:Tumor Burden / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D047228:Angiotensin II Type 1 Receptor Blockers; D000970:Antineoplastic Agents; D044140:Receptor, Angiotensin, Type 1; D042461:Vascular Endothelial Growth Factor A; D019808:Losartan